Dr Diane Roberts
University of Manchester
Jean McFarlane Building
PACT: Peer support to maintain psychological wellbeing in people with advanced cancer. A feasibility study for a Randomised Controlled Trial (V1)
The aim of this study is to determine the feasibility of delivering and investigating a novel peer mentor intervention to promote and maintain psychological wellbeing in people with advanced cancer using a randomised controlled trial design.
Wales Research Ethics Committee 5 Bangor, 03/02/2016, ref: 16/WA/0032
Interventional; Design type: Prevention, Process of Care, Education or Self-Management, Psychological & Behavioural, Complex Intervention
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Specialty: Cancer, Primary sub-specialty: Palliative and supportive care; UKCRC code/ Disease: Cancer/ Malignant neoplasms of ill-defined, secondary and unspecified sites
Patients completing baseline assessment (T=0) will be allocated to either intervention or control group using a telephone system provided by Manchester Academic Health Science Centre Clinical Trials Unit (MAHSC-CTU). Carers will NOT be randomised independently but will be considered as belonging to intervention or control group according to the allocation of the associated patient.
Intervention Group: Patients will be preference matched with a trained volunteer mentor for a period of 12 weeks during which time they will meet/communicate in various ways according to personal preference to facilitate peer learning of coping strategies. Patients will continue to receive ‘usual care’ i.e. all those therapies and clinical interventions/services which would be offered in the absence of the study intervention. Carers will not be actively involved in receipt of the intervention but will be assessed for indirect effects.
Control group: Patients allocated to the control group will solely receive usual care for the 12 weeks of the study.
Participants in both groups are followed up after 4 and 12 weeks. Additionally, a sub-group of participants from each category (patient, carer, mentor or health professional) will be interviewed at baseline and 12 weeks (or earlier exit from the study).
Primary outcome measures
Patient and carer psychological wellbeing is measured using the WHO Quality of Life-BREF questionnaire (WHOQOL-BREF) at baseline, 4 and 12 weeks.
Secondary outcome measures
1. Patient and carer psychological wellbeing (WHOQOL-BREF) at T = 12 weeks (or completion of intervention if before 12 weeks).
2. Patient health related quality of life is measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ C 15 PAL) at baseline, 4 and 12 weeks (or completion of intervention if before 12 weeks)
3. Patient and carer coping strategies is measured using the Brief Coping Orientation for Problems Experienced (Brief COPE) questionnaire at baseline, 4 and 12 weeks (or completion of intervention if before 12 weeks)
4. Patient depression is measured using the Patient Health Questionnaire (PHQ-9) at baseline, 4 and 12 weeks (or completion of intervention if before 12 weeks)
5. Social Support is measured using the modified Medical Outcomes Study Social Support Survey (mMOS-SS) in patient participants, and the Carer Support Needs Assessment Tool (CSNAT) questionnaire in carer participants) at baseline, 4 and 12 weeks (or completion of intervention if before 12 weeks)
Overall trial start date
Overall trial end date
Participant inclusion criteria
Patient inclusion criteria:
1. Aged 16 years and over
2. With advanced cancer (any type), defined as metastatic disease at diagnosis, and/or with local or metastatic spread following treatment and/or where prognosis is estimated as less than a year. Those whom their health care professionals judge to have a prognosis > 3 months to facilitate study completion.
3. Those whom their health care professionals judge have capacity to give informed consent to research participation.
4. Assessed by their health care professional as understanding their diagnosis of advanced cancer.
5. Able to adequately understand and respond to verbal and written material in English.
Peer Mentor inclusion criteria:
1. Experience of living with cancer
2. At least six months post diagnosis
3. Aged 18 years and over
4. Able to commit to six months of volunteering
5. Have at least two hours per week available for volunteering
6. Live in the geographic area selected for the project
7. Fluency in written and spoken English
8. Qualitative demonstration of empathy, compassion, and open and non-didactic communication skills
9. Satisfactory completion of project-specific training (assessed by research team)
10. DBS clearance for working with vulnerable people.
Carer and Professional Participants:
Recruited patients will be asked to nominate one “person they get most support from”, and an invitation to participate sent to this identified carer. In addition, patient participants will nominate one healthcare professional providing cancer and/or palliative care to them on a regular basis, and an invitation to participate will be sent to this identified healthcare professional.
Target number of participants
Planned Sample Size: 60; UK Sample Size: 60
Participant exclusion criteria
1. Aged under 16 years
2. With advanced cancer prognosis < 3 months
3. Those whom their health care professionals judge not to have capacity to give informed consent to research participation
4. Assessed by their health care professional as not understanding their diagnosis of advanced cancer
Peer Mentor criteria:
1. No experience of living with cancer
2. Less than months post diagnosis
3. Aged under 18 years
4. Unable to commit to six months of volunteering
5. ave less than two hours per week available for volunteering
6. Live outside the geographic area selected for the project
7. No qualitative demonstration of empathy, compassion, and open and non-didactic communication skills
8. Unable to be granted DBS clearance for working with vulnerable people
1. Aged under 18 years
2. Caring for someone with an advanced cancer prognosis < 3 months
3. Those whom patient's health care professionals judge not to have capacity to give informed consent to research participation
4. Assessed by the patient's health care professional as not understanding the associated patient's diagnosis of advanced cancer
No exclusion criteria
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
The Christie NHS Foundation Trust
Oncology Unit Wilmslow Road
Trial participating centre
Clatterbridge Cancer Centre NHS Foundation Trust
Clatterbridge Health Park Clatterbridge Road
National Institute for Health Research
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
1. Planned publication of articles covering several aspects of the study including mentor training and design
2. Planned dissemination of results through professional and academic conferences or similar routes
Intention to publish date
Participant level data
To be made available at a later date
Results - basic reporting